Physician profile
William R Dickerman
NPI 1487668174
$18,550.11
in general payments reported to CMS, 2019-2025
79 companies · $2,413 in 2025
The $2,413 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,232 · 2020: $2,132 · 2021: $2,413 · 2022: $2,574 · 2023: $3,012 · 2024: $2,774 · 2025: $2,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,179 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,178.57 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,881.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,695.04 | 2019-2025 | |
| Lilly USA, LLC | $1,478.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,325.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,272.62 | 2021-2025 | Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $1,120.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $737.83 | 2023-2025 | Gemtesa, Aptiom |
| Merck Sharp & Dohme LLC | $671.68 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $654.18 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $582.20 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $513.69 | 2021-2025 | |
| Astellas Pharma US INC | $479.85 | 2019-2025 | Veozah |
| Amgen INC. | $440.16 | 2019-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $386.33 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $352.70 | 2019-2023 |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dickerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.